BioCentury | Nov 7, 2019
Product Development

AZ replants R&D roots in China, goes all-in on innovation

...MAPK3; and Abbisko Therapeutics Co. Ltd. licensed AZD4547...
BioCentury | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

...of EGFR inhibitor Tarceva erlotinib, PI3K inhibitor buparlisib, dual CDK4/CDK6 inhibitor Ibrance palbociclib, FGFR inhibitor AZD4547...
...in Phase II for solid tumors and diffuse large B cell lymphoma (DLBCL). AZ has AZD4547...
BioCentury | Jun 16, 2018
Product Development

MATCH’s long game

...Both drugs are from Roche and its Genentech Inc. unit. Arm W tested AstraZeneca plc’s AZD4547...
...pretty unusual diseases.” James Doroshow, NCI Nevertheless, NCI’s James Doroshow told BioCentury the Kadcyla and AZD4547...
...biomarker analyses of patients in the NCI-MATCH Kadcyla arm are not completed. Sorting mutations The AZD4547...
BioCentury | May 18, 2018
Clinical News

NCI-MATCH arms fall short in ASCO abstracts

...adenocarcinomas. Among 41 patients with fibroblast growth factor receptor (FGFR) aberrations in an arm receiving AZD4547...
...two (5%) patients had a PR and 51% had stable disease; there were no CRs. AZD4547...
...a Phase III trial to treat HER2-negative advanced or metastatic breast cancer. Data from the AZD4547...
BioCentury | May 16, 2018
Clinical News

NCI-MATCH arms fall short in ASCO abstracts

...adenocarcinomas. Among 41 patients with fibroblast growth factor receptor (FGFR) aberrations in an arm receiving AZD4547...
...two (5%) patients had a PR and 51% had stable disease; there were no CRs. AZD4547...
...a Phase III trial to treat HER2-negative advanced or metastatic breast cancer. Data from the AZD4547...
BioCentury | Mar 13, 2018
Distillery Techniques

Biomarkers

...inhibitor AZD4547 compared with a scrambled shRNA, and culturing for 14 days in 1 μM AZD4547...
...using PHLDA1 expression to predict which patients would respond to drug therapies. AstraZeneca plc has AZD4547...
...Feb. 27, 2018 doi:10.1016/j.celrep.2018.02.028 CONTACT: Richard Grose, Barts Cancer Institute, London, U.K. email: r.p.grose@qmul.ac.uk Jaime De Leon AZD4547 Herceptin...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Jul 14, 2016
Distillery Therapeutics

Therapeutics: Fibroblast growth factor receptor 1 (FGFR1; CD331); MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2); K-Ras (KRAS)

...alone. Also in the cell lines, Mekinist plus the FGFR1 inhibitors Iclusig ponatinib, infigratinib or AZD4547...
...in Phase II testing for solid tumors. AstraZeneca plc has the tyrosine kinase inhibitor AZD4547...
BioCentury | Mar 7, 2016
Clinical News

Opdivo nivolumab: Phase II/III amended

...dependent kinase 4 (CDK4) and CDK6 inhibitor from Pfizer Inc. (NYSE:PFE, New York, N.Y.); and AZD4547...
BioCentury | Mar 2, 2016
Clinical News

Lung-MAP adds non-biomarker Opdivo arm

...cyclin dependent kinase 4 ( CDK4 ) and CDK6 inhibitor from Pfizer Inc. (NYSE:PFE); and AZD4547...
Items per page:
1 - 10 of 24